These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 19931593)

  • 21. Serotonin-1A receptor gene polymorphism and the ability of antipsychotic drugs to improve attention in schizophrenia.
    Sumiyoshi T; Tsunoda M; Higuchi Y; Itoh T; Seo T; Itoh H; Suzuki M; Kurachi M
    Adv Ther; 2010 May; 27(5):307-13. PubMed ID: 20533011
    [TBL] [Abstract][Full Text] [Related]  

  • 22. No association between the brain-derived neurotrophic factor gene Val66Met polymorphism and tardive dyskinesia in schizophrenic patients.
    Kang SG; Choi JE; An H; Lim SW; Lee HJ; Han C; Kim YK; Kim SH; Cho SN; Lee MS; Joe SH; Jung IK; Kim L
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1545-8. PubMed ID: 18602732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic analysis of the TrkB gene and schizophrenia in the Japanese population: Juntendo University Schizophrenia Projects (JUSP).
    Higashi M; Higashi S; Ohnuma T; Shibata N; Sakai Y; Arai H
    Neurosci Lett; 2007 Sep; 425(1):1-5. PubMed ID: 17720314
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Pharmacogenetic assessment of antipsychotic-induced tardive dyskinesia: contribution of 5-hydroxytryptamine 2C receptor gene and of a combination of dopamine D3 variant allele (Gly) and MnSOD wild allele (Val)].
    Zhang Z; Hou G; Zhang X; Yao H; Sha W; Zhang X
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2003 Apr; 20(2):98-102. PubMed ID: 12673575
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pathway-based association analysis of genome-wide screening data suggest that genes associated with the gamma-aminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia.
    Inada T; Koga M; Ishiguro H; Horiuchi Y; Syu A; Yoshio T; Takahashi N; Ozaki N; Arinami T
    Pharmacogenet Genomics; 2008 Apr; 18(4):317-23. PubMed ID: 18334916
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia.
    Kaiser R; Tremblay PB; Klufmöller F; Roots I; Brockmöller J
    Mol Psychiatry; 2002; 7(7):695-705. PubMed ID: 12192613
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduced expression of regulator of G-protein signaling 2 (RGS2) in hypertensive patients increases calcium mobilization and ERK1/2 phosphorylation induced by angiotensin II.
    Semplicini A; Lenzini L; Sartori M; Papparella I; Calò LA; Pagnin E; Strapazzon G; Benna C; Costa R; Avogaro A; Ceolotto G; Pessina AC
    J Hypertens; 2006 Jun; 24(6):1115-24. PubMed ID: 16685212
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects?
    Le Hellard S; Theisen FM; Haberhausen M; Raeder MB; Fernø J; Gebhardt S; Hinney A; Remschmidt H; Krieg JC; Mehler-Wex C; Nöthen MM; Hebebrand J; Steen VM
    Mol Psychiatry; 2009 Mar; 14(3):308-17. PubMed ID: 18195716
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Suggestive association between the C825T polymorphism of the G-protein beta3 subunit gene (GNB3) and clinical improvement with antipsychotics in schizophrenia.
    Müller DJ; De Luca V; Sicard T; King N; Hwang R; Volavka J; Czobor P; Sheitman BB; Lindenmayer JP; Citrome L; McEvoy JP; Lieberman JA; Meltzer HY; Kennedy JL
    Eur Neuropsychopharmacol; 2005 Oct; 15(5):525-31. PubMed ID: 16139171
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association analysis of the RGS4 gene in Han Chinese and Scottish populations with schizophrenia.
    Zhang F; St Clair D; Liu X; Sun X; Sham PC; Crombie C; Ma X; Wang Q; Meng H; Deng W; Yates P; Hu X; Walker N; Murray RM; Collier DA; Li T
    Genes Brain Behav; 2005 Oct; 4(7):444-8. PubMed ID: 16176390
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association study of dopamine transporter gene and schizophrenia in Korean population using multiple single nucleotide polymorphism markers.
    Jeong SH; Joo EJ; Ahn YM; Kim YS
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Sep; 28(6):975-83. PubMed ID: 15380858
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia.
    Basile VS; Ozdemir V; Masellis M; Meltzer HY; Lieberman JA; Potkin SG; Macciardi FM; Petronis A; Kennedy JL
    Mol Psychiatry; 2001 Mar; 6(2):230-4. PubMed ID: 11317228
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serotonin receptor 2A gene polymorphisms and schizophrenia: association with family history, diagnostic subtype and height in patients.
    Melkersson K; Hulting AL
    Neuro Endocrinol Lett; 2009; 30(3):343-51. PubMed ID: 19855357
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alteration in RGS2 expression level is associated with changes in haloperidol induced extrapyramidal features in a mutant mouse model.
    Greenbaum L; Lifschytz T; Zozulinsky P; Broner EC; Slonimsky A; Kohn Y; Lerer B
    Eur Neuropsychopharmacol; 2012 May; 22(5):379-86. PubMed ID: 21982117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of RGS2 gene polymorphisms with suicide and increased RGS2 immunoreactivity in the postmortem brain of suicide victims.
    Cui H; Nishiguchi N; Ivleva E; Yanagi M; Fukutake M; Nushida H; Ueno Y; Kitamura N; Maeda K; Shirakawa O
    Neuropsychopharmacology; 2008 Jun; 33(7):1537-44. PubMed ID: 17728697
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RGS2 ggenetic variation: association analysis with panic disorder and dimensional as well as intermediate phenotypes of anxiety.
    Hohoff C; Weber H; Richter J; Domschke K; Zwanzger PM; Ohrmann P; Bauer J; Suslow T; Kugel H; Baumann C; Klauke B; Jacob CP; Fritze J; Bandelow B; Gloster AT; Gerlach AL; Kircher T; Lang T; Alpers GW; Ströhle A; Fehm L; Wittchen HU; Arolt V; Pauli P; Hamm A; Reif A; Deckert J
    Am J Med Genet B Neuropsychiatr Genet; 2015 Apr; 168B(3):211-22. PubMed ID: 25740197
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of genetic variations of regulator of G-protein signaling 2 with hypertension in the general Xinjiang Kazakh population.
    Li NF; Zhang JH; Yang J; Zhou L; Luo WL; Guo YY; Yao XG; Wang HM; Chang JH
    Clin Exp Hypertens; 2010; 32(5):256-61. PubMed ID: 20662725
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of RGS2 and RGS5 variants with schizophrenia symptom severity.
    Campbell DB; Lange LA; Skelly T; Lieberman J; Levitt P; Sullivan PF
    Schizophr Res; 2008 Apr; 101(1-3):67-75. PubMed ID: 18262772
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hypertension after preeclampsia and relation to the C1114G polymorphism (rs4606) in RGS2: data from the Norwegian HUNT2 study.
    Kvehaugen AS; Melien Ø; Holmen OL; Laivuori H; Dechend R; Staff AC
    BMC Med Genet; 2014 Mar; 15():28. PubMed ID: 24593135
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic variation and the risk of haloperidol-related parkinsonism in elderly patients: a candidate gene approach.
    Knol W; van Marum RJ; Jansen PA; Strengman E; Al Hadithy AF; Wilffert B; Schobben AF; Ophoff RA; Egberts TC
    J Clin Psychopharmacol; 2013 Jun; 33(3):405-10. PubMed ID: 23609402
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.